INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line

被引：18

作者：

Colombo, N. ^{[1
,2
]}

Gadducci, A. ^{[3
]}

Sehouli, J. ^{[4
]}

Biagioli, E. ^{[5
]}

Nyvang, G-B. ^{[6
,7
]}

Riniker, S. ^{[8
]}

Montes, A. ^{[9
]}

Ottevanger, N. ^{[10
]}

Zeimet, A. G. G. ^{[11
]}

Vergote, I. B. ^{[12
]}

Funari, G. ^{[5
]}

Baldoni, A. ^{[13
]}

Tognon, G. ^{[14
]}

De Censi, A. ^{[15
]}

Churruca Galaz, C. ^{[16
]}

Chekerov, R. ^{[4
]}

Maenpaa, J. ^{[17
]}

Rulli, E. ^{[5
]}

Fossati, R. ^{[5
]}

Poveda, A. ^{[18
]}

机构：

[1] European Inst Oncol IRCCS, Gynecol Canc Program, Milan, Italy

[2] Univ Milano Bicocca, Milan, Italy

[3] Univ Pisa, Clin & Expt Med, Div Obstet & Gynecol, Pisa, Italy

[4] Charite Berlin Univ Med, Gynecol Ctr Oncol Surg, European Competence Ctr Ovarian Canc, Berlin, Germany

[5] Ist Ric Farmacol Mario Negri IRCCS, Oncol, Milan, Italy

[6] NSGO CTU, Oncol, Odense, Denmark

[7] Odense Univ Hosp, Odense, Denmark

[8] Kantonsspital St Gallen, Oncol, St Gallen, Switzerland

[9] Guys & St Thomas NHS Fdn Trust, Oncol, London, England

[10] Radboud Univ Nijmegen Med Ctr, Med Oncol, Nijmegen, Netherlands

[11] Innsbruck Med Univ, Gynecol & Obstet, Innsbruck, Austria

[12] Univ Hosp Leuven, Gynecol, Campus Gasthuisberg, Leuven, Belgium

[13] Ist Oncol Veneto, Oncol 2, Padua, Italy

[14] Univ Brescia, ASST Spedali Civili, Obstet & Gynaecol, Brescia, Italy

[15] EO Osped Galliera, SC Oncol Med, Genoa, Italy

[16] HU Donostia Onkol, Med Oncol Serv, UGC Oncol Gipuzkoa, Donostia San Sebastian, Spain

[17] Tampere Univ Hosp Tays, Obstet & Gynaecol, Tampere, Finland

[18] Hosp Quironsalud, Gynecol Oncol, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2260

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA30

引用

页码：S1161 / S1161

页数：1